Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.

This study is the first to demonstrate the relationship between bevacizumab concentrations, target involvement and clinical efficacy by effectively mitigating potential sources of bias. Most of target amount may be tumoral in mCRC. Future studies should provide a more in-depth description of this relationship.